Expanded Access Programs (EAPs) in Europe

Are they right for your therapy? By Maximus Rex & Nicola Allen Drug development is a long and costly process. It is not uncommon for a new drug candidate to take more than 13 years to progress from discovery to being commercially available, w i t h costs often exceeding $1 billion for the manufacturer…

Read more

Webinar 2: U.S. lessons learnt from Kymriah & Luxturna

In the second of three webinars, P4A is focussing on the US environment for gene therapies. Single application cell and gene therapies in the US face health insurance challenges driven by a short-term focus, disconnection between price reporting and outcomes value, and complex distribution models…

Read more